...the U.S. for the indication (see BioCentury, July 19, 2010). Further details were not disclosed. Novalar Pharmaceuticals Inc....

...Osaka:4508)/Novartis AG (NYSE:NVS; SIX:NOVN) Gilenya fingolimod (FTY720) Relapsing-remitting multiple sclerosis (RRMS) MAA action Early 2011 Novalar Pharmaceuticals Inc./sanofi-aventis...

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar...
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...
...license to all European countries. OraVerse is already approved in the U.S. for the indication. Novalar Pharmaceuticals Inc....

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar Pharmaceuticals Inc....
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...

...FDA approved an NDA from Novalar (San Diego, Calif.) for OraVerse phentolamine (formerly NV-101 ) to...
...anesthetic. The application was reviewed under section 505(b)(2) of the Food, Drug and Cosmetic Act. Novalar...

...New Enterprise Associates. Existing investors Domain Associates; SR One; and Montreux Equity Partners also participated. Novalar's...
...The company expects to launch NV-101 next year. Domain's Bob More was appointed chairman of Novalar...

...acetate (EVA) fiber is in preclinical testing. The institute is eligible for milestones and royalties. Novalar Pharmaceuticals Inc....